Arvinas Inc (ARVN)
32.66
+0.55
(+1.71%)
USD |
NASDAQ |
May 17, 16:00
31.01
-1.65
(-5.05%)
Pre-Market: 20:00
Arvinas Cash from Operations (TTM): -354.10M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -354.10M |
| December 31, 2023 | -347.80M |
| September 30, 2023 | -335.90M |
| June 30, 2023 | -317.70M |
| March 31, 2023 | -307.60M |
| December 31, 2022 | -273.50M |
| September 30, 2022 | -238.00M |
| June 30, 2022 | 510.10M |
| March 31, 2022 | 541.30M |
| December 31, 2021 | 559.40M |
| September 30, 2021 | 566.14M |
| Date | Value |
|---|---|
| June 30, 2021 | -137.75M |
| March 31, 2021 | -111.75M |
| December 31, 2020 | -89.70M |
| September 30, 2020 | -76.89M |
| June 30, 2020 | -52.65M |
| March 31, 2020 | -44.82M |
| December 31, 2019 | -40.60M |
| September 30, 2019 | -36.70M |
| June 30, 2019 | -49.54M |
| March 31, 2019 | -48.15M |
| December 31, 2018 | -16.12M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-354.10M
Minimum
Mar 2024
566.14M
Maximum
Sep 2021
-31.90M
Average
-83.29M
Median
Cash from Operations (TTM) Benchmarks
| Pfizer Inc | 8.578B |
| Johnson & Johnson | 23.19B |
| Bristol-Myers Squibb Co | 13.72B |
| Janux Therapeutics Inc | -51.50M |
| ACADIA Pharmaceuticals Inc | 63.71M |